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1.1. Need for developing case definitions and guidelines for data
collection, analysis, and presentation for spontaneous abortion and
ectopic pregnancy as adverse events following immunization during
pregnancy
Vaccine-preventable infectious diseases are responsible for
maternal, morbidity and mortality. Immunization of pregnantwomen can protect against vaccine-preventable infections, and
may have the added benefit of direct fetal protection. Outcomes
of spontaneous abortion and ectopic pregnancy following maternal
receipt of vaccination have been less studied. There have been few
prospective clinical trials evaluating vaccination in pregnancy;
most safety data available are derived from registries where out-
comes are passively reported.
Spontaneous abortion and ectopic pregnancy are important
pregnancy outcomes that should be included in vaccine
registries or included as important outcomes in vaccine research.
As many organizations define pregnancy loss uniquely we
will compare and contrast the existing definitions and provide
guidance for use of this adverse event term in studies of maternal
immunization.
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HPV human papillomavirus
IIV Inactivated influenza vaccines
MMR Measles, mumps, rubella
MR Measles, rubella
SA Spontaneous abortion
TT Tetanus toxoid
Td Tetanus, diphtheria vaccine
TdaP Tetanus, diphtheria, pertussis vaccine
TVUS Transvaginal ultrasound
VAERS Vaccine Adverse Event Reporting System
WHO World Health OrganizationDefinition and diagnosis of spontaneous abortion and ectopic
pregnancy
First trimester spontaneous abortion (Less than 14 weeks 0 days
gestation)
Many terms have been used to describe the failure of an early
pregnancy, including: early pregnancy loss, early pregnancy fail-
ure, miscarriage, and spontaneous abortion. Pregnancy failure
can be further classified as inevitable, missed, anembryonic, or
embryonic demise [1,2]. For the purposes of this document, we will
use the term ‘‘spontaneous abortion” (‘‘SA”) to describe early preg-
nancy loss. Various national and international organizations have
released guidelines for the diagnosis and/or workup of suspected
early or first trimester spontaneous abortion, which are presented
in the Tables.
Second trimester spontaneous abortion (Between 14 weeks 0 days
and 21 weeks 6 days)
The arbitrary division by gestational age between abortion and
stillbirth complicates the definition and diagnostic criteria for sec-
ond trimester abortion. Existing definitions are outlined in the
Tables.
Ectopic pregnancy
Ectopic pregnancy is one in which the pregnancy implants in a
location other than the uterine endometrium. While most ectopic
pregnancies occur in the fallopian tube (up to 97%), pregnancies
can also implant in the abdomen, cervix, ovary and cornua of the
uterus [3]. Society guidelines agree that the evaluation of a woman
with a pregnancy of uncertain location should include an ultra-
sound examination followed by serum measurement of beta
human chorionic gonadotropin (b-HCG) level if no intrauterine
pregnancy is identified by ultrasound. If the serum b-HCG is above
the discriminatory zone (the serum b-HCG level at which an
intrauterine pregnancy should be visible, generally around
1500–2000 mIU/ml) and no intrauterine pregnancy is identified,
an ectopic pregnancy is likely [3–5]. It should be noted that these
society guidelines are primarily applicable for high resource
settings given reliance on ultrasound for diagnosis, whereas the
definitions in this document can be applied to all settings.
Induced abortion
While a full case definition for induced abortion is not included
in this document, we recommend reporting this as a pregnancy
outcome of interest. Induced abortion is the termination of preg-
nancy through medical or surgical procedures. Guidelines for safe,
comprehensive care of women with induced abortion have been
published by many groups, including the World Health Organiza-
tion (WHO), the American Congress of Obstetricians and Gynaecol-
ogists (ACOG), the Royal College of Obstetricians and
Gynaecologists (RCOG), the Royal Australian and New Zealand
College of Obstetricians and Gynaecologists (RANZCOG), and theSociety of Obstetricians and Gynaecologists of Canada (SOGC)
[6–11].
Epidemiology of spontaneous abortion and ectopic pregnancy
Spontaneous abortion (SA) is a common outcome. Published
frequency of SA reported by several authors varies depending on
the definition used [12–27]. In one systematic review study, the
cumulative risk of SA for weeks 5 through 20 of gestation ranged
from 11 to 22 miscarriages per 100 women (11–22%) [28]. This
number varies by age group and study population, with women
over 35 years of age experiencing the highest rates of SA [29],
depending on gestational age, with a higher risk of SA earlier in
gestation [30].
Ectopic pregnancy is a serious adverse pregnancy outcome and
is one of the most common causes of maternal mortality in early
pregnancy [31]. Because, particularly in high resource areas, it
can be treated in the outpatient setting (the visits for which are
not easily tracked) confirming the incidence of ectopic pregnancy
is challenging. Reported rates range generally range from 0.6% to
2.4% [32–36]. These rates may be increasing secondary to an
increase in the use of assisted reproductive technologies and in
pelvic infection [36]. The case mortality rate varies between low
and high resource settings. The mortality rate for ectopic preg-
nancy in the United Kingdom is 3.6/10,000 cases [37]; this rate is
ten times higher in developing countries [38], which may be in part
explained by the difficulty diagnosing and managing ectopics in
regions with limited availability of ultrasound and/or quantitative
HCG.
Causes and risk factors of spontaneous abortion
The most common and well-documented cause of sponta-
neous abortion is aneuploidy, or abnormal chromosome number
(genetic factors) [39]. Studies have shown that approximately
50% of spontaneous abortions are associated with fetal chromoso-
mal abnormalities [39]. Many studies have shown that maternal
age is also a risk factor for SA. A Danish registry study that exam-
ined the outcomes of more than 1.2 million pregnancies [29]
demonstrated that the risk of spontaneous loss is three times
higher in women age 40 or older as compared to the under 25
age group, making age a stronger risk factor than any other
known effect [39]. Other risk factors include paternal age, previ-
ous pregnancy loss, thyroid abnormalities, pre-gestational dia-
betes, congenital uterine anomalies, exposure to lead, mercury,
organic solvents and ionizing radiation, smoking and alcohol
use [39]. A recent UK population based case-control study, found
the following factors to be independently associated with SA after
adjustment for confounding: high maternal age, previous SA, pre-
vious pregnancy termination and infertility, assisted conception,
low pre-pregnancy body mass index, regular or high alcohol con-
sumption, feeling stressed (including trend with number of
stressful or traumatic events), high paternal age and conception
occurring after a change in partner [40]. Additionally, multiparity
carries a risk of reproductive failure, so pregnancy order, desired
family size, and maternal age should be used in consideration of
the etiology of SA [41]. Paternal exposures should also be consid-
ered when studying SA because theoretically any exposure of
either parent prior to conception (i.e. males during spermatogen-
esis and females around time of conception and during preg-
nancy) could increase the risk of spontaneous loss [41].
Importantly, the risk of spontaneous abortion is inversely related
to week of gestation; in one study, for example, the risk of SA at 6
completed weeks of gestation was found to be 9.4% while the risk
at 10 completed weeks was 0.7% [42].
Several studies have suggested that certain psychological fac-
tors can contribute to the risk for SA, such as affective disorders
(depression, dysthymia and mania), and anxiety disorders, includ-
ing: agoraphobia, generalized anxiety disorder, panic disorder,
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[40,43–54].
Causes and risk factors of ectopic pregnancy
Prior tubal surgery, in particular tubal ligation, is associated
with very high rates of ectopic pregnancy. A large retrospective
cohort study showed that while sterilization failure after tubal
ligation is rare (0.1 to 0.8% in the first year after the procedure),
approximately 1/3 of the resulting pregnancies were ectopic [55].
Use of an intrauterine device (IUD) is similarly associated with very
low rates of pregnancy (0.5 per 100 users in 5 years for the levo-
norgesterel [LNG] device), but high rates of ectopic pregnancy (1
in 2) for those women who did conceive with the LNG-IUD
in situ [56]. For women who conceive with the copper containing
IUD in site, the ectopic pregnancy rate is 1 in 16 [57].
A prior history of ectopic pregnancy is another important risk
factor for ectopic pregnancy, with recurrence rates ranging from
8 to 15%, depending on the modality used to treat the previous
ectopic [58]. Women with a history of diethylstilbestrol exposure
in utero also have an increased risk of ectopic pregnancy, with
rates 9 times higher than baseline [59]. Pelvic infection, including
that resulting from gonorrhea or chlamydia, is a major contributor
to ectopic pregnancy risk. The rate of ectopic pregnancy in a
woman with a history of one chlamydial infection was found to
be 0.13%; this rate increased to 0.49% after two chlamydial infec-
tions, and rose to 1.4% after three or more infections [60]. Multiple
reports have found an increase in ectopic pregnancy risk with
assisted reproductive technology, with rates ranging from 2.2% to
4.5% [61–63].
Spontaneous abortion following immunization
Data from clinical trials and observational studies support the
safety of inactivated vaccines or toxoids (e.g., tetanus, pertussis
or influenza) for maternal immunization in many parts of the
world.
a. Influenza vaccines:
Inactivated influenza vaccines (IIV) are recommended for use in
pregnant women regardless of trimester due to the increased risk
of infection and complications during pregnancy [64–66]. System-
atic reviews for inactivated influenza virus vaccines did not find an
association with SA and IIV, although the majority of maternal
immunization studies are focused on the vaccines containing the
influenza A (H1N1) pandemic antigen and limited data exists dur-
ing the first trimester [67–70]. Preliminary results of 2010–11 and
2011–12 seasons’ data show an increased risk of SA following IIV
among pregnant women in the 1–28 day risk window who had
received a pH1N1-containing vaccine the prior influenza season,
adjusted odds ratio (aOR) 2.0 (95% CI 1.1–3.6) [71]. However these
findings are inconsistent with prior research on IIV safety in preg-
nancy. Safety studies continue, and follow-up studies are planned
in more recent influenza seasons.
b. Tetanus-containing vaccines:
Fewer data exist regarding spontaneous abortion risk following
administration of tetanus-toxoid containing vaccines (e.g., TT, Td,
TdaP). In countries where maternal and neonatal tetanus remains
a public health concern, the WHO recommends that in the absence
of a reliable vaccination history or completion of the childhood
vaccination series, pregnant women receive tetanus vaccination
[72]. Additionally, In the past half-decade, TdaP has been intro-
duced for routine use in pregnant women in a number of countries
(e.g., Argentina, Israel, New Zealand, the United Kingdom, and the
United States) to protect newborn infants against pertussis [73].
Because the recommended vaccination timing for TdaP is thirdtrimester (to optimize maternal antibody response and transfer
of antibodies to the infant) [66,73], it is anticipated that the major-
ity of pregnant women receiving the vaccine will do so after the
period of risk for a spontaneous abortion (i.e., after 22 weeks ges-
tation). However, the existing data do not support an increased risk
for spontaneous abortion following TdaP vaccination during preg-
nancy. One small cohort study in the United States conducted prior
to routine vaccination during pregnancy reported a lower rate of
spontaneous or elective abortions among 138 women receiving
TdaP during pregnancy, as compared to 552 pregnant women
who did not receive the vaccine (2.9% vs. 8.9%) [74]. The remaining
data on spontaneous abortion risk following pertussis-containing
vaccines comes from passive surveillance, including an analysis
of the Vaccine Adverse Event Reporting System (VAERS) in the Uni-
ted States [75]. The VAERS analysis included more than 3 years of
data following the recommendation to routinely vaccinate preg-
nant women with TdaP and found no evidence for any increase
in the number of spontaneous abortion reports.
Several vaccines are not recommended for administration in
pregnancy, including but not limited to those outlined below, are
often inadvertently administered to women of reproductive age,
and therefore unintentional exposures during pregnancy may
occur. Most live vaccines are contraindicated or not recommended
for use during pregnancy because of the theoretical risk of trans-
mission of the virus to the fetus through the placenta [65].
c. Human papillomavirus vaccines:
Vaccines against human papillomavirus (HPV) are not recom-
mended for use during pregnancy, but because they are often
administered to women of reproductive age, they may be inadver-
tently administered during early pregnancy. Overall, the data col-
lected as part of pregnancy registries, epidemiological studies
and unintended exposures during clinical trials on HPV vaccines
are mostly reassuring with respect to pregnancy outcomes data,
including spontaneous abortion [76–79], however specific studies
of these vaccines in pregnant women were not conducted and
the available safety data are insufficient to draw definite
conclusions.
d. Meningococcal vaccines:
Evidence on the safety of administration of meningococcal vac-
cination during pregnancy is scarce. Information on spontaneous
abortion risk following immunization with quadrivalent meningo-
coccal conjugate vaccines (MCV4) is derived from passive surveil-
lance, including a VAERS analysis that did not find any safety
concerns [80]. As of June 2015, over 220 million individuals
between the ages 1 and 29 years have received a new monovalent
meningococcal A conjugate vaccine in 15 countries of the African
belt, as part of mass immunization campaign that includes preg-
nant women [81,82]. An observational cohort study conducted in
Ghana did not observe any difference in risk of spontaneous abor-
tion among 1730 immunized pregnant women (0.9%), as compared
to 919 concurrent unvaccinated controls (0.7%) or 3551 historical
unvaccinated controls (1.0%) [83]. To date, no data are available
on the safety of monovalent meningococcal B vaccines, currently
licensed for use in Europe and the United States, when adminis-
tered during pregnancy.
e. Rubella and varicella vaccines:
Rubella and varicella are of specific interest because of the
potential sequelae of wild-type infection in susceptible pregnant
women, which could hypothetically cause congenital rubella
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on safety of measles, rubella (MR) and varicella vaccines has exam-
ined congenital anomalies outcomes. Data on spontaneous abor-
tion risk following MR vaccines are derived from adverse events
registries and exposure-based registries, including a VAERS analy-
sis of MMR (measles, mumps, rubella) vaccine and surveillance for
cases during mass MR vaccination campaigns in several countries
in Central and South America. Although limited, these data do
not indicate any concerns related to spontaneous abortion risk
[84–87]. An exposure based registry of pregnant women inadver-
tently receiving varicella vaccine also found no evidence for a
safety signal for spontaneous abortion [88].
f. Oral polio virus vaccine:
Oral polio virus vaccine, which contains live attenuated polio-
virus types 1, 2, and 3, has been used to protect pregnant women
andneonates against poliomyelitis since its introduction in the early
1960s. While immunization of adults with poliovirus vaccine is not
routinely recommended if the series is completed during childhood,
immunization of pregnant women at high risk of endemic or epi-
demic exposure is recommended by WHO and several national
immunization technical advisory groups [65]. Limited data on spon-
taneous abortion following polio virus vaccination exist. In Israel,
one study examined rates of spontaneous abortion during a mass
oral polio virus vaccination program that was prompted by a polio
epidemic in 1988. During the epidemic, over 90% of the population,
including pregnant women, was administered oral polio virus vac-
cine, and the number of spontaneous abortions was similar both
before (October through December 1987) and during the vaccina-
tion campaign (October through December 1988) [89].
Ectopic pregnancy following immunization
Data from clinical trials and observational studies on ectopic
pregnancy following immunization are scarce.1.2. Methods for the development of the case definitions and guidelines
for data collection, analysis, and presentation for spontaneous
abortion and ectopic pregnancy as adverse events following
immunization during pregnancy
Following the process described in the overview paper [90] as
well as on the Brighton Collaboration Website http://www.
brightoncollaboration.org/internet/en/index/process.html, the
Brighton Collaboration Abortion Working Group was formed in
2015 and included members of clinical, academic, public health,
research and industry background. The composition of the working
and reference group as well as results of the web-based survey
completed by the reference group with subsequent discussions in
the working group can be viewed at: http://www.brightoncollabo-
ration.org/internet/en/index/working_groups.html.
To guide the decision-making for the case definition and guide-
lines, a literature search was performed using Medline, Embase
and the Cochrane Libraries, including the terms abortion, miscar-
riage, spontaneous abortion, induced abortion, elective abortion,
ectopic pregnancy, pregnancy loss, blighted ovum, anembryonic
pregnancy, vaccine, immunization, maternal, pregnancy, vaccine,
safety and vaccination. Exhaustive search strategies were imple-
mented using appropriate key words, accepted MeSH words, and
combinations thereof. All abstracts were screened for possible
reports of abortion following immunization. Searches were
restricted to references in English, and involving only human sub-
jects. Multiple general medical, pediatric, obstetrics and infectious
disease text books were also searched. For vaccines without pub-
lished data, reviewed package inserts were reviewed (specifically
for HPV9). Centers for Disease Control and Prevention AdvisoryCommittee on Immunization Practices (CDC ACIP) presentations
available on the web for relevant studies were also reviewed.
The search and screening resulted in the identification of articles
with potentially relevant material for further evaluation. This liter-
ature provided several different general definitions for abortion, its
epidemiology, numerous descriptions for abortion causes and/or
risk factors and the diagnostic criteria put forth. Most publications
addressing abortion following immunization were case reports of
single cases or case series describing various pregnancy outcomes,
for which terminology was very inconsistent and very few used
case definitions. There was no publication identified addressing
ectopic pregnancy as an outcome following immunization.
1.3. Rationale for selected decisions about the case definition of
spontaneous abortion and the case definition of ectopic pregnancy as
adverse events following immunization during pregnancy
Related term(s)
As previously mentioned, for the purposes of this document, we
will be using exclusively the terms ‘‘spontaneous abortion” and
‘‘ectopic pregnancy.” There are many terms in use to describe preg-
nancy loss, including pregnancy failure, miscarriage, and sponta-
neous abortion, which can be further classified into threatened,
inevitable, and missed abortion, anembryonic pregnancy, or
embryonic demise.
Formulating a case definition that reflects diagnostic certainty:
weighing specificity versus sensitivity
It needs to be re-emphasized that the grading of definition levels
is entirely about diagnostic certainty, not clinical severity of an
event. Detailed information about the severity of the event should
always be recorded, as specified by the data collection guidelines.
The number of symptoms and/or signs that will be documented
for each case may vary considerably. The case definition has been
formulated such that the Level 1 definition is highly specific for
the condition. As maximum specificity normally implies a loss of
sensitivity, two additional diagnostic levels have been included
in the definition, offering a stepwise increase of sensitivity from
Level One down to Level Three, while retaining an acceptable level
of specificity at all levels. In this way it is hoped that all possible
cases of spontaneous abortion/ectopic pregnancy can be captured.
Rationale for individual criteria or decision made related to the
case definition
There is a need to consider data sources and availability of exist-
ing data when defining pregnancy outcomes in research. The inter-
pretation of data is difficult when definitions of commonly used
terms differ in the literature. Flexibility and alignmentwith existing
definitions where studies/surveillance are performed are necessary
to ensure comparability and interpretation of data. Sometimes
these data are not made available. As previously discussed, sponta-
neous abortion and ectopic pregnancy are relatively common preg-
nancy outcomes. Given that vaccination is also a common practice
in pregnancy, there is a need for development of precise definitions
of pregnancy outcomes. Careful studies are required in which
appropriate controls are chosen and where the background rates
of the pregnancy outcomes of concern are known. Furthermore,
while recording of these common outcomes is important, it is clear
that it must be done so using precise, predefined criteria in order to
avoid any unmerited concern about an association of between
spontaneous abortion or ectopic pregnancy and vaccination.
Determination of the gestational age at onset of the event
A proposed algorithm for estimating gestational age for studies
in various community settings is presented in a related manuscript
[91]. We propose utilizing this algorithm when reporting cases of
spontaneous abortion/ectopic pregnancy following vaccine
administration.
Table 1
Conventional definitions for spontaneous abortion.
Source/
Group
Gestational
age (weeks)
Birth
weight
(grams)
Height criteria
(crown-heel length)
Definition
USA (NCHS,
CDC, ICD)
19 6/7 <350 The National Center for Health Statistics, and the Centers for Disease Control and Prevention,
defines abortion as pregnancy termination prior to 20 weeks gestation or a fetus born weighing
less than 500 g. Despite this, definitions vary widely according to state laws. The Model Law
recommends the limit for fetal death reporting for those that occur at 350 g or more or, if the
weight is unknown, of 20 completed weeks’ gestation or more. A program exists for voluntary
reporting of abortions of less than 20 weeks; but a fetal death certificate is not mandatory. [92]
The International Classification of Diseases, 10th revision (ICD-10) defines spontaneous abortion
as: ‘‘the loss of pregnancy from natural causes before the 20th week of pregnancy.” The definition
includes the assumption that, expulsion of products of conception occurs without deliberate
interference and before the fetus is viable thus weighing less than 500 g
WHO 21 6/7 <500 <25 The World Health Organization (WHO) defines spontaneous abortion as: ‘‘termination of
pregnancy by expulsion of embryo/fetus before 22 weeks of pregnancy or below 500 g of weight.
The legal requirements for the registration of fetal deaths and therefore the threshold to consider
a stillbirth versus abortion vary from country to country and even within countries. WHO
recommends that, if possible, all fetuses weighing at least 500 g at birth, whether alive or dead,
should be included in the statistics. When information on birth weight is unavailable, the
corresponding criteria for gestational age (22 completed weeks) or body length (25 cm crown-
heel) should be used [93]
EMA 21 6/7 The European Medicines Agency uses the term spontaneous abortion as the synonym of early fetal
death, which is the pregnancy ending spontaneously before 22 weeks of gestation (i.e. up to and
including 21 6/7 weeks of gestation) [94]
UK (RCOG) 23 6/7 The United Kingdom defines abortion as a fetus born before the 24th week of pregnancy (i.e. non-
viable fetus) that does not show any signs of life or a fetus expelled after the 24th week of
pregnancy provided it was no longer alive by the 24th week (this fact being known or provable
from the stage of development by the dead fetus) [95]
3 The case definition should be applied when there is no clear alternative diagnosis
for the reported event to account for the combination of symptoms.
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There is recognition that the gestational age used to define first
and, in particular, second trimester spontaneous abortion varies
between and even within countries (see Table 1). However, we
have chosen the cut-offs presented in this document in a pragmatic
manner for the purposes of classification of pregnancy outcomes.
Specifically, we have chosen to define a spontaneous abortion as
a pregnancy loss that occurs up to 21 weeks 6 days, with outcomes
after that gestational age pertaining to the stillbirth or preterm
birth categories. This then represents a ‘‘harmonized” suggested
cut-off with no bearing over legal or reporting requirement issues.
We strongly emphasize that this gestational age cut-off should be
used for research and data collection purposes only, and is not
intended to inform or impact clinical care.
Timing post immunization in pregnancy
The time interval from immunization to onset of spontaneous
abortion or ectopic pregnancy is not part of the definition, but it
is recommended to be used in the data analysis to examine factors
such as temporal clusters as well as determining whether the out-
come of interest occurred before or after the vaccine exposure.
Where feasible, details of this interval should be assessed and
reported as described in the data collection guidelines (see guide-
line 34, Section 3.2).
1.4. Guidelines for data collection, analysis and presentation
As mentioned in the overview paper [90], the case definition is
accompanied by guidelines that are structured according to the
steps of conducting a clinical trial, i.e. data collection, analysis
and presentation. Neither case definition nor guidelines are
intended to guide or establish criteria for management of ill
infants, children, or adults, but were instead developed to improve
data comparability.
1.5. Periodic review
Similar to all Brighton Collaboration case definitions and guide-
lines, review of the definition with its guidelines is planned on a
regular basis (i.e. every three to five years) or more often if needed.2. Case definitions of spontaneous abortion and ectopic
pregnancy3
For all levels of diagnostic certainty, the definitions of sponta-
neous abortion and ectopic pregnancy must include:
– Determination of absence of a viable pregnancy (see Table 2)
AND.
– Determination of fetal gestational age through maternal infor-
mation OR through fetal information [91].
2.1. Spontaneous abortion and ectopic pregnancy ascertainment of
levels of certainty
The ultimate level of certainty for the diagnosis of spontaneous
abortion should incorporate the level of certainty for gestational
age, such that even if the level of certainty about the diagnosis of
spontaneous abortion is a Level 1, if the pregnancy dating is poor
(Level 3), the diagnosis of spontaneous abortion becomes less cer-
tain, which the level should reflect, and should be reported as the
same level as the pregnancy dating in this case, Level 3.
Gestational age assessment: Should be determined using the
Brighton Preterm Birth Gestational Age algorithm [91].
2.2. First trimester spontaneous abortion
2.2.1. Documentation of all aspects is required for level of
ascertainment
Level 1 (Highest level, gold standard diagnosis, maximum
sensitivity and specificity)Crown-rump length >7 mm and no visible heartbeat on
transvaginal ultrasound
OR
Crown-rump length >15 mm and no visible heartbeat on
transvaginal ultrasound
Table 2
Current society guidelines for diagnosing spontaneous abortion.
ACOG 19 6/7 First trimester
Non-viable, intrauterine pregnancy with either an empty gestational sac or a gestational sac containing an embryo or fetus
without fetal heart activity within the first 12 6/7 weeks of gestation.
Findings diagnostic of spontaneous abortion (first trimester)
Crown-rump length (CRL) of 7 mm of greater and no heartbeat
Mean sac diameter of 25 mm or greater and no embryo
Absence of embryo with heartbeat 2 weeks or more after an ultrasound that showed a gestational sac without a yolk sac
Absence of embryo with heartbeat 11 days or more after an ultrasound that showed a gestational sac with a yolk sac
Second trimester
Spontaneous pregnancy loss after the first trimester and before 20 weeks gestation
[96]
NICE/RANZCOG/RCOG Evaluation with transvaginal ultrasound
If the mean gestational sac diameter is less than 25 mm and there is no visible fetal pole then perform a second ultrasound a
minimum of 7 days after the first before making a diagnosis
If the mean gestational sac diameter is 25 mm or more and there is no visible fetal pole then seek a second opinion on the
viability of the pregnancy and/or perform a second ultrasound a minimum of 7 days after the first
If the CRL is less than 7 mm and there is no visible heartbeat, perform a second ultrasound a minimum of 7 days after the
first before making a diagnosis, and even more scans may be needed
If the CRL is 7 mm or more and there is no visible heartbeat, then one can seek a second opinion and/or perform a second
ultrasound a minimum of 7 days after the first before making a decision regarding viability of the pregnancy
Evaluation with transabdominal ultrasound
If there is no visible heartbeat when the CRL is measured then record the size of the CRL and perform a second scan a
minimum of 14 days after the first scan
Serum B-HCG should not be used alone to determine the viability of a pregnancy of unknown location.
[5]
SGOC 23 6/7 First trimester
Mean gestational sac diameter exceeds 8 mm without a yolk sac by transvaginal ultrasound
Mean gestational sac diameter exceeds 16 mm without an embryo by transvaginal ultrasound
Gestational sac greater than 20 mm without a yolk sac by transabdominal ultrasound
Gestational sac 25 mm without an embryo by transabdominal ultrasound
No cardiac activity in an embryo greater than 5 mm by transvaginal ultrasound or 9 mm by transabdominal ultrasound
Second Trimester
All spontaneous pregnancy losses from 13 weeks of gestation until the fetus reaches viability, 24 weeks gestation
[4]
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sac diameter >25 mm and no visible embryo or yolk sac
AND
Second transvaginal ultrasound >7 days later (or 14 days
later if transabdominal) confirming diagnosis of non-viable
pregnancy
OR
Absence of embryo with heartbeat >2 weeks after a transab-
donimal scan that showed a gestational sac without a yolk
sac
OR
Absence of embryo with heartbeat >11 days after a
transvaginal scan that showed a gestational sac with a yolk
sac
OR
Gestational age within pre-defined range for selected abor-
tion definition as assessed by maternal and/or fetal parame-
ters (Level 1–2) (using the Brighton Preterm Birth
Gestational Age algorithm).
AND
Positive urine or blood pregnancy test that becomes negative
after 7 days
OR
Products of conception found on histopathological evaluation of
pregnancy tissue
OR
Ultrasound examination demonstrating an empty uterine cavity
in a woman who had clear evidence of intrauterine pregnancy
on previous ultrasound examination
ORVaginal bleeding, external cervical or open or closed with visi-
ble expulsion of pregnancy tissue/products of conception
Level 2 (Missing at least one confirmatory diagnostic param-
eter, remains sensitive and specific)
Does not qualify as a level 1
Crown-rump length > 7 mm and no visible heartbeat, con-
firmed on transvaginal ultrasound
OR
Crown-rump length > 15 mm and no visible heartbeat, con-
firmed on transvaginal ultrasound
OR
Mean gestational sac diameter is 25 mm or more and no vis-
ible embryo
Gestational age within pre-defined range for selected abortion
definition as assessed by maternal and/or fetal parameters
(Level 1–2) (using Brighton Preterm Birth Gestational Age
algorithm).
Level 3. (Less sensitive, with specificity)
Does not qualify as a level 1 or level 2
AND
Gestational age within pre-defined range for selected abor-
tion definition as assessed by maternal and/or fetal parame-
ters (Level 3) (using Brighton Preterm Birth Gestational Age
algorithm).
Level 4 (Reported spontaneous abortion with insufficient
evidence to meet the case definition)
Does not qualify as a level 1, 2 or 3
AND
Maternal self-report or documentation in medical record
without sufficient ultrasound or laboratory evidence to
confirm
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2.3.1. Documentation of all aspects is required for level of
ascertainment
The ultimate level of certainty for the diagnosis of sponta-
neous abortion should incorporate the level of certainty for
gestational age, such that even if the level of certainty about
the diagnosis of abortion is a Level 1, if the pregnancy dating
is poor (Level 2), the diagnosis of abortion becomes less cer-
tain, which the level should reflect, and should be reported
as the same level as the pregnancy dating in this case,
Level 2.
Gestational age assessment: Should be determined using the
Brighton Preterm Birth Gestational Age algorithm.
Level 1 (Highest level, gold standard diagnosis, maximum
sensitive and specificity)Gestational age within pre-defined range for selected abor-
tion definition as assessed by maternal and/or fetal-neonatal
parameters (Level 1–2) (using Brighton Preterm Birth Gesta-
tional Age algorithm).
AND
No visible heartbeat on ultrasound
OR
Visible expulsion of pregnancy tissues/products of concep-
tion on examination of the cervix
OR
Products of conception found on histopathological evalua-
tion of uterine contents
Level 2 (Missing at least one important parameter; remains
sensitive, specific)
Does not qualify as a level 1
AND
Gestational age within pre-defined range for selected abor-
tion definition as assessed by maternal and/or fetal parame-
ters (Level 3) (using Brighton Preterm Birth Gestational Age
algorithm).
AND
No visible heartbeat on ultrasound
OR
Visible expulsion of pregnancy tissues/products of concep-
tion on examination of the cervix
OR
Products of conception found on histopathological evalua-
tion of uterine contents
Level 3
No level 3 definition for second trimester
Level 4 (Reported abortion with insufficient evidence to
meet the case definition)
Does not qualify as a level 1 or 2
AND
Maternal self-report or documentation in medical record
without sufficient ultrasound or laboratory evidence to
confirm
2.4. Ectopic pregnancy
2.4.1. Documentation of all aspects is required for level of
ascertainment
Level 1 (Highest level, gold standard diagnosis, maximum
sensitive and specificity)Gestational age within pre-defined range for selected ecto-
pic pregnancy definition as assessed by maternal and/or
fetal-neonatal parameters (Level 1–2) (using Brighton Pre-
term Birth Gestational Age algorithm).AND
B-HCG serum blood test >2000 mlU/ml
AND
TVUS showing no intrauterine pregnancy
OR
Gestational age within pre-defined range for selected ecto-
pic pregnancy definition as assessed by maternal and/or
fetal-neonatal parameters (Level 1–2) (using Brighton Pre-
term Birth Gestational Age algorithm).
AND
TVUS showing extrauterine pregnancy
OR
No products of conception found on endometrial curettage
after D&C procedure
Level 2 (Missing at least one important parameter; remains
sensitive, specific)
Does not qualify as a level 1
AND
Gestational age within pre-defined range for selected ecto-
pic pregnancy definition as assessed by maternal and/or
fetal-neonatal parameters (Level 1–2) (using Brighton Pre-
term Birth Gestational Age algorithm).
AND
TVUS showing no intrauterine pregnancy
OR
No products of conception found on endometrial curettage
after D&C procedure
Level 3 (Less sensitive, with specificity)
Does not qualify as a level 1 or level 2
AND
Gestational age within pre-defined range for selected ecto-
pic pregnancy definition as assessed by maternal and/or
fetal-neonatal parameters (Level 2–3) (using Brighton Pre-
term Birth Gestational Age algorithm).
AND
Positive urine pregnancy test
AND
No products of conception found on endometrial curettage
after D&C procedure
Level 4 (Reported ectopic pregnancy with insufficient evi-
dence to meet the case definition)
Does not qualify as a level 1, 2 or 3
AND
Maternal self-report or documentation in medical record
without sufficient ultrasound or laboratory evidence to
confirm3. Guidelines for data collection, analysis and presentation of
spontaneous abortion/ectopic pregnancy
It was the consensus of the Brighton Collaboration sponta-
neous abortion/ectopic pregnancy Working Group to recommend
the following guidelines to enable meaningful and standardized
collection, analysis, and presentation of information about these
events. However, implementation of all guidelines might not be
possible in all settings. The availability of information may vary
depending upon resources, geographical region, and whether the
source of information is a prospective clinical trial, a post-mar-
keting surveillance or epidemiological study, or an individual
report of abortion. Also, as explained in more detail in the over-
view paper in this volume, these guidelines have been developed
by this working group for guidance only, and are not to be con-
sidered a mandatory requirement for data collection, analysis, or
presentation.
5 The date and/or time of onset is defined as the time post immunization, when the
first sign or symptom indicative for abortion occurred. This may only be possible to
determine in retrospect.
6 The date and/or time of first observation of the first sign or symptom indicative
for abortion can be used if date/time of onset is not known.
7 The date of diagnosis of an episode is the day post immunization when the event
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These guidelines represent a desirable standard for the collec-
tion of available pregnancy outcome data following immunization
to allow comparability. The guidelines are not intended to guide
the primary reporting of these events to a surveillance system.
Investigators developing a data collection tool based on these data
collection guidelines also need to refer to the criteria in the case
definition, which are not repeated in these guidelines.
Guidelines 1–46 below have been developed to address data
elements for the collection of adverse event information as speci-
fied in general drug safety guidelines by the International Confer-
ence on Harmonization of Technical Requirements for
Registration of Pharmaceuticals for Human Use [97], and the form
for reporting of drug adverse events by the Council for Interna-
tional Organizations of Medical Sciences [98]. These data elements
include an identifiable reporter and patient, one or more prior
immunizations, and a detailed description of the adverse event,
in this case, of abortion following immunization. The additional
guidelines have been developed as guidance for the collection of
additional information to allow for a more comprehensive under-
standing of spontaneous abortion/ectopic pregnancy following
immunization.
3.1.1. Source of information/reporter
For all cases and/or all study participants, as appropriate, the
following information should be recorded:
(1) Date of report.
(2) Name and contact information of person4 reporting the event
as specified by country specific data protection law.
(3) Relationship of the reporter to the vaccine recipient [e.g.,im-
munizer (clinician, nurse) attending physician, family mem-
ber [indicate relationship, self [vaccine recipient], other.
3.1.2. Vaccinee/control
3.1.2.1. Demographics. For all cases and/or all study participants
(i.e. pregnant women), as appropriate, the following information
should be recorded:
(4) Case study participant identifiers (first name initial followed
by last name initial) or code (or in accordance with country-
specific data protection laws).
(5) Date of birth, age of patient.
(6) Gestational age.
(7) Country of residence.
(8) Occupation(s).
3.1.2.2. Clinical and immunization history. For all cases and/or all
study participants, as appropriate, the following information
should be recorded:
(9) Past medical history, including hospitalizations, underlying
diseases/disorders, pre-immunization signs and symptoms
including identification of indicators for, or the absence of,
a history of allergy to vaccines, vaccine components or med-
ications; food allergy; allergic rhinitis; eczema; asthma.
(10) Any medication history (other than treatment for the event
described) prior to, during, and after immunization includ-
ing prescription and non-prescription medication as well
as medication or treatment with long half-life or long term4 If the reporting center is different from the vaccinating center, appropriate and
timely communication of the adverse event should occur.effect (e.g. immunoglobulins, blood transfusion and
immune-suppressants) or substance abuse (e.g. narcotics
or other recreational drug, alcohol or smoking).
(11) Immunization history (i.e. previous immunizations and any
adverse event following immunization (AEFI), in particular
occurrence of the same event after a previous immunization.
(12) Clinical confirmation of pregnancy prior to maternal
immunization.
3.1.3. Details of the immunization
For all cases and/or all study participants, as appropriate, the
following information should be recorded:
(13) Date and time of immunization(s).
(14) Description of all vaccine (s), including name of vaccines,
manufacturer, lot number, expiration date, multi or mono
dose vial, volume (e.g. 0.25 Ml, 0.5 mL, etc.), dose number
if part of series of immunizations against the same disease
(s), description of the adjuvants and any diluents, and the
manufacturer, lot number, and expiration date of any dilu-
ents used.
(15) The anatomical sites (including left or right side) of all
immunizations (e.g. vaccine A in proximal left lateral thigh,
vaccine B in left deltoid).
(16) Route and method of administration (e.g. intramuscular,
intradermal, subcutaneous, and needle-free (including type
and size), other injection devices).
(17) Needle length and gauge.
(18) If the immunization is part of:met the
8 The
definitio
9 Exa
therape Routine immunization program
 Preventive mass immunization campaign
 Mass immunization campaign for outbreak response
 Domestic travel from non-endemic to endemic area
 International travel
 Occupational risk3.1.4. The adverse event
For all cases at any level of diagnostic certainty and for reported
events with insufficient evidence, the criteria fulfilled to meet the
case definition should be recorded.
Specifically document (if available):
(If data not available because of regulatory guidelines, please
specify data cannot be disclosed.)
(19) Clinical description of signs and symptoms of spontaneous
abortion or ectopic pregnancy, and if there was medical con-
firmation of the event (i.e. patient seen by physician).
(20) Date/time of onset,5 first observation6 and diagnosis7; as well
as end of episode8 and final outcome.9
(21) Concurrent signs, symptoms, exposures and diseases.
(22) Pregnancy details: Pregnancy details: date of last normal menstrual period,
ultrasound examinations, antenatal care visits, preg-
nancy-related illnesses and complications.case definition at any level.
end of an episode is defined as the time the event no longer meets the case
n at the lowest level of the definition.
mple: recovery to pre-immunization health status, spontaneous resolution,
utic intervention, persistence of the event, sequelae, death.
10 An
the foll
inpatien
results
birth de
meets t
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laboratory examinations, other clinical tests, surgical
and/ or pathological findings and diagnosis preferable to
perform at reliable and accredited laboratories. If more
than one measurement of particular parameters is taken
and recorded, the value corresponding to the largest
deviation from the expected normal value or range of
parameter should be reported.
 Spontaneous abortion or ectopic pregnancy details:
specifically document (if available) mode of treatment
(e.g. dilation and curettage, etc) and complications, if
any (e.g. hemorrhage, infection, ruptured ectopic preg-
nancy, etc.).(23) Measurement/testing
 Values and units of routinely measured parameters (e.g.
temperature, blood pressure) – in particular those indi-
cating the severity of the event;
 Method of measurement (e.g. type of thermometer, oral
or other route duration of measurement, etc.);
 Results of laboratory examinations, surgical and/or
pathological findings and diagnoses if present.(24) Treatment given for the event, especially specify what and
dosing, if applicable.
(25) Outcome8 at last observation (e.g. for an event thatmeets the
case definition of spontaneous abortion, it results in death of
the embryo/fetus but not necessarily the mother). Add
descriptions if maternal death occurred. Also, for multiple
gestation, if concomitant twin death occurred. For example:
 Recovery to pre- immunization health status
 Spontaneous resolution
 Ongoing treatment/recovering
 Persistence of the event/unresolved
 Significant complications of treatment/sequelae
 Maternal death and description of any other outcome11 To determine the appropriate category, the user should first establish, whether a
reported event meets the criteria for the lowest applicable level of diagnostic
certainty, e.g. Level three. If the lowest applicable level of diagnostic certainty of the
definition is met, and there is evidence that the criteria of the next higher level of
diagnostic certainty are met, the event should be classified in the next category. This
approach should be continued until the highest level of diagnostic certainty for a
given event could be determined. major criteria can be used to satisfy the
requirement of minor criteria. If the lowest level of the case definition is not met, it(26) Objective clinical evidence supporting classification of the
event as ‘‘serious”10 (i.e. results in death of the embryo/fetus,
hospitalisation of the mother).
(27) Exposures other than the immunization before and after
immunization (e.g. trauma, induced, environmental) consid-
ered potentially relevant to the reported event.
3.1.5. Miscellaneous/general
(28) The duration of follow-up reported during the surveillance
period should be predefined likewise. It should aim to con-
tinue to resolution of the event (i.e. the outcome of the preg-
nancy is captured).
(29) Methods of data collection should be consistent within and
between study groups, if applicable.
(30) Follow-up of cases should attempt to verify and complete
the information collected as outlined in data collection
guidelines 1–27.
(31) Guidance should be provided to optimize the quality and
completeness of information.
(32) Reports of pregnancy outcomes should be collected through-
out the study period regardless of the time elapsed between
immunization and the adverse event. If this is not feasible
due to the study design, the study periods during which
safety data are being collected should be clearly defined.AEFI is defined as serious by international standards if it meets one or more of
owing criteria: 1) it results in death, 2) is life-threatening, 3) it requires
t hospitalisation or results in prolongation of existing hospitalisation, 4)
in persistent or significant disability/incapacity, 5) is a congenital anomaly/
fect, 6) is a medically important event or reaction. For abortion, the event
he definition of serious (i.e. it results in death of the embryo/fetus).(33) The safety monitoring should take into account:should
the eve
12 If t
missing
evidenc
13 An
finding
should Biologic characteristics of the vaccines (e.g., live attenu-
ated versus inactivated component vaccines).
 The vaccine preventable-disease.
 Non clinical and clinical data obtained previously and
 Characteristics of the target population (e.g., nutrition,
underlying disease like immunocompromised illness).
(34) Methods of data collection should be consistent within and
between study groups or surveillance systems, if applicable.
(35) Reports of pregnancy outcomes should be collected through-
out the study period regardless of the time elapsed between
immunization and the adverse event. If this is not feasible
due to the study design, the study periods during which
safety data are being collected should be clearly defined.
3.2. Data analysis
The following guidelines represent a desirable standard for
analysis of data on spontaneous abortion and ectopic pregnancy
to allow for comparability of data, and are recommended as an
addition to data analyzed for the specific study question and
setting.
(36) Reported events should be classified in one of the following
five categories including the three levels of diagnostic cer-
tainty. Events that meet the case definition should be classi-
fied according to the levels of diagnostic certainty as
specified in the case definition. Events that do not meet
the case definition should be classified in the additional cat-
egories for analysis.
Event classification in 5 categories11
Event meets case definition
(1) Level 1: Criteria as specified in the case definition
(2) Level 2: Criteria as specified in the case definition
(3) Level 3: Criteria as specified in the case definition
Event does not meet case definition
Additional categories for analysis
(4) Reported event with insufficient evidence to meet the case
definition12
(5) Not a case of spontaneous abortion/ectopic pregnancy13
(37) The interval between immunization and reported abortion
could be defined as the date/time of immunization (last vac-
cination) to the date/time of onset 4 of the event, consistent
with the definition. It is important to note that timing of
fetal demise may differ by days to weeks from the time
when a spontaneous abortion or ectopic pregnancy is clini-
cally recognized. If few cases are reported, the concrete timebe ruled out that any of the higher levels of diagnostic certainty are met and
nt should be classified in additional categories four or five.
he evidence available for an event is insufficient because information is
, such an event should be categorised as ‘‘reported abortion with insufficient
e to meet the case definition”.
event does not meet the case definition if investigation reveals a negative
of a necessary criterion (necessary condition) for diagnosis. Such an event
be rejected and classified as ‘‘Not a case of abortion”.
6572 C.E. Rouse et al. / Vaccine 35 (2017) 6563–6574course could be analyzed for each; for a large number of
cases, data can be analyzed in the following increments for
identification of temporal clusters:
Subjects with spontaneous abortion or ectopic pregnancy by
interval to presentationInterval⁄ Number<24 h after immunization
2–<7 days after immunization
8–<42 days after immunization
>42 days after immunization
Weekly unit increments thereafter
Total14 Use of this document should preferably be referenced by referring to the
respective link on the Brighton Collaboration website (http://www.brightoncollabo-(38) If more than one measurement of a particular criterion is
taken and recorded, the value corresponding to the greatest
magnitude of the adverse experience could be used as the
basis for analysis. Analysis may also include other character-
istics like qualitative patterns of criteria defining the event.
(39) The distribution of data (as numerator and denominator
data) could be analyzed in predefined increments (e.g. mea-
sured values, times), where applicable. Increments specified
above should be used. When only a small number of cases is
presented, the respective values or time course can be pre-
sented individually.
(40) Data on spontaneous abortion/ectopic pregnancy obtained
from subjects receiving a vaccine should be compared
with those obtained from an appropriately selected and
documented control group(s) to assess background rates
in non-exposed populations, and should be analyzed by
study arm and dose where possible, e.g. in prospective
clinical trials. It should be emphasized that because risk
of spontaneous abortion/ectopic pregnancy is time-depen-
dent (i.e. inversely related to week of gestation [42],
choosing appropriate control groups is paramount. For
example, if a group receiving vaccination is compared to
a group receiving a placebo but the women in the vaccine
arm receive the vaccine at 6 weeks gestation and the con-
trol women receive the placebo at 8 weeks, the rate of SA
after the vaccination will be higher, reflecting differences
in background risk.
3.3. Data presentation
These guidelines represent a desirable standard for the presen-
tation and publication of data on abortion following immunization
to allow for comparability of data, and are recommended as an
addition to data presented for the specific study question and set-
ting. Additionally, it is recommended to refer to existing general
guidelines for the presentation and publication of randomized con-
trolled trials, systematic reviews, and meta-analyses of observa-
tional studies in epidemiology (e.g. statements of Consolidated
Standards of Reporting Trials (CONSORT) [99], of Improving the
quality of reports of meta-analyses of randomized controlled trials
(QUORUM) [100], and of Meta-analysis Of Observational Studies in
Epidemiology (MOOSE) [101], respectively).
(41) All reported events should be presented according to the cat-
egories listed in guideline 36.
(42) Data on possible abortion events should be presented in
accordance with data collection guidelines 1–35 and data
analysis guidelines 36–40.
(43) Data should be presented with numerator and denominator
(n/N) (and not only in percentages), if available.Although immunization safety surveillance systems denom-
inator data are usually not readily available, attempts should
be made to identify approximate denominators. The source
of the denominator data should be reported and calculations
of estimates be described (e.g. manufacturer data like total
doses distributed, reporting through Ministry of Health, cov-
erage/population based data, etc.).
(44) The incidence of cases in the study population should be
presented and clearly identified as such in the text.
(45) If the distribution of data is skewed, median and inter-quar-
tile range are usually the more appropriate statistical
descriptors than a mean. However, the mean and standard
deviation should also be provided.
(46) Any publication of data on pregnancy outcomes should
include a detailed description of the methods used for data
collection and analysis as possible. It is essential to specify:ration.o The study design;
 The method, frequency and duration of monitoring for
pregnancy outcomes;
 The trial profile, indicating participant flow during a
study including drop-outs and withdrawals to indicate
the size and nature of the respective groups under
investigation;
 The type of surveillance (e.g. passive or active
surveillance);
 The characteristics of the surveillance system (e.g. popu-
lation served, mode of report solicitation);
 The search strategy in surveillance databases;
 Comparison group(s), if used for analysis;
 The instrument of data collection (e.g. standardized ques-
tionnaire, diary card, report form);
 Whether the day of immunization was considered ‘‘day
one” or ‘‘day zero” in the analysis;
 Whether the date of onset 4) and/or the date of first
observation 5 and/or the date of diagnosis 6 was used
for analysis; and
 Use of this case definition, in the abstract or methods sec-
tion of a publication14.Disclaimer
The findings, opinions and assertions contained in this consen-
sus document are those of the individual scientific professional
members of the working group. They do not necessarily represent
the official positions of each participant’s organization. Specifically,
the findings and conclusions in this paper are those of the authors
and do not necessarily represent the views of their respective
institutions.Acknowledgements
The authors are grateful for the support and helpful comments
provided by the Brighton Collaboration Steering Committee and
Reference Group, as well as other experts consulted as part of
the process. The authors are also grateful to Jan Bonhoeffer, Jorgen
Bauwens of the Brighton Collaboration Secretariat and Sonali
Kochhar of Global Healthcare Consulting for final revisions of the
final document. We would also to acknowledge the contributions
made by Karalee Scheaffer, Information Scientist SciInteL, Pasteur,
Swiftwater PA, for contributions made to the literature review.
Finally, we would like to thank the members of the WHO/CIOMS
Working Group on Vaccine Pharmacovigilance (http://rg).
C.E. Rouse et al. / Vaccine 35 (2017) 6563–6574 6573www.cioms.ch/frame_current_programme.htm) for the review of,
constructive comments on, and endorsement of this document.Appendix A. Supplementary material
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.vaccine.2017.01.
047.References
[1] Farquharson RG, Jauniaux E, Exalto N. ESHRE special interest group for early
pregnancy (SIGEP). Updated and revised nomenclature for description of
early pregnancy events. Hum Reprod 2005;20:3008–11.
[2] Kolte AM, Bernardi LA, Christiansen OB, Quenby S, Farquharson RG, Goddijn
M, et al. Terminology for pregnancy loss prior to viability: a consensus
statement from the ESHRE early pregnancy special interest group. Hum
Reprod 2015;30:495–8.
[3] American College of Obstetricians and Gynecologists. ACOG practice bulletin
no: 94. Medical management of ectopic pregnancy. Obstet Gynecol
2008;111:1479–85.
[4] Morin L, Van den Hof MC. Society of obstetricians and gynaecologists of
Canada. SOGC clinical practice guidelines. Ultrasound evaluation of first
trimester pregnancy complications. Number 161, June 2005. Int J Gynaecol
Obstet 2006;93:77–81.
[5] National Collaborating Centre for Women’s and Children’s Health. Ectopic
pregnancy and miscarriage: diagnosis and initial management in early
pregnancy of ectopic pregnancy and miscarriage. Royal College of
Obstetricians and Gynaecologists; 2012.
[6] ACOG Practice Bulletin No. 135: Second-trimester abortion. Obstet Gynecol
2013;121:1394–406.
[7] American College of Obstetricians and Gynecologists. Practice bulletin no.
143: medical management of first-trimester abortion. Obstet Gynecol
2014;123:676–92.
[8] The Royal Australian and New Zealand College of Obstetricians and
Gynaecologists. C-Gyn 17: Termination of pregnancy 3/2005.
[9] The Royal College of Obstetricians and Gynaecologists. The care of women
requesting induced abortion (evidence-based clinical guideline no. 7); 2011.
[10] Davis VJ. Induced abortion guidelines. J Obstet Gynaecol Can
2006;28:1014–27.
[11] World Health Organization, Department of Reproductive Health and
Research. Safe abortion: technical and policy guidance for health systems,
2nd edition; 2012.
[12] Wilcox AJ, Weinberg CR, O’Connor JF, Baird DD, Schlatterer JP, Canfield RE,
et al. Incidence of early loss of pregnancy. N Engl J Med 1988;319:189–94.
[13] Ellish NJ, Saboda K, O’Connor J, Nasca PC, Stanek EJ, Boyle C. A prospective
study of early pregnancy loss. Hum Reprod 1996;11:406–12.
[14] Zinaman MJ, Clegg ED, Brown CC, O’Connor J, Selevan SG. Estimates of human
fertility and pregnancy loss. Fertil Steril 1996;65:503–9.
[15] Wang X, Chen C, Wang L, Chen D, Guang W, French J. Conception, early
pregnancy loss, and time to clinical pregnancy: a population-based
prospective study. Fertil Steril 2003;79:577–84.
[16] Regan L, Braude PR, Trembath PL. Influence of past reproductive performance
on risk of spontaneous abortion. BMJ 1989;299:541–5.
[17] Blohm F, Fridén B, Milsom I. A prospective longitudinal population-based
study of clinical miscarriage in an urban Swedish population. BJOG
2008;115:176–82. discussion 183.
[18] Goldhaber MK, Fireman BH. The fetal life table revisited: spontaneous
abortion rates in three Kaiser Permanente cohorts. Epidemiology
1991;2:33–9.
[19] Saraiya M, Berg CJ, Shulman H, Green CA, Atrash HK. Estimates of the annual
number of clinically recognized pregnancies in the United States, 1981–1991.
Am J Epidemiol 1999;149:1025–9.
[20] Devine S, West S, Andrews E, Tennis P, Hammad TA, Eaton S, et al. The
identification of pregnancies within the general practice research database.
Pharmacoepidemiol Drug Saf 2010;19:45–50.
[21] Herbert D, Lucke J, Dobson A. Pregnancy losses in young Australian women:
findings from the Australian Longitudinal Study on Women’s Health.
Womens Health Issues 2009;19:21–9.
[22] Jones RK, Kost K. Underreporting of induced and spontaneous abortion in the
United States: an analysis of the 2002 National Survey of Family Growth. Stud
Fam Plann 2007;38:187–97.
[23] Buss L, Tolstrup J, Munk C, Bergholt T, Ottesen B, Grønbaek M, et al.
Spontaneous abortion: a prospective cohort study of younger women from
the general population in Denmark. Validation, occurrence and risk
determinants. Acta Obstet Gynecol Scand 2006;85:467–75.
[24] Eskild A, Vatten LJ, Nesheim B-I, Vangen S. The estimated risk of miscarriage
should be corrected for induced abortion rates. Acta Obstet Gynecol Scand
2009;88:569–74.
[25] Gray RH, Wu LY. Subfertility and risk of spontaneous abortion. Am J Public
Health 2000;90:1452–4.[26] Hemminki E, Forssas E. Epidemiology of miscarriage and its relation to
other reproductive events in Finland. Am J Obstet Gynecol
1999;181:396–401.
[27] Li D-K, Odouli R, Wi S, Janevic T, Golditch I, Bracken TD, et al. A population-
based prospective cohort study of personal exposure to magnetic fields
during pregnancy and the risk of miscarriage. Epidemiology 2002;13:9–20.
[28] Ammon Avalos L, Galindo C, Li D-K. A systematic review to calculate
background miscarriage rates using life table analysis. Birth Defects Res A
Clin Mol Teratol 2012;94:417–23.
[29] Nybo Andersen AM, Wohlfahrt J, Christens P, Olsen J, Melbye M. Maternal age
and fetal loss: population based register linkage study. BMJ
2000;320:1708–12.
[30] Savitz DA, Hertz-Picciotto I, Poole C, Olshan AF. Epidemiologic measures of
the course and outcome of pregnancy. Epidemiol Rev 2002;24:91–101.
[31] Say L, Chou D, Gemmill A, Tunçalp Ö, Moller A-B, Daniels J, et al. Global causes
of maternal death: a WHO systematic analysis. Lancet Glob Health 2014;2:
e323–33.
[32] Hoover KW, Tao G, Kent CK. Trends in the diagnosis and treatment of ectopic
pregnancy in the United States. Obstet Gynecol 2010;115:495–502.
[33] Stulberg DB, Cain LR, Dahlquist I, Lauderdale DS. Ectopic pregnancy rates in
the Medicaid population. Am J Obstet Gynecol 2013;208. 274.e1-7.
[34] Seror V, Gelfucci F, Gerbaud L, Pouly J-L, Fernandez H, Job-Spira N, et al. Care
pathways for ectopic pregnancy: a population-based cost-effectiveness
analysis. Fertil Steril 2007;87:737–48.
[35] Ikeme ACC, Ezegwui HU. Morbidity and mortality following tubal ectopic
pregnancies in Enugu, Nigeria. J Obstet Gynaecol 2005;25:596–8.
[36] Walker JJ. Ectopic pregnancy. Clin Obstet Gynecol 2007;50:89–99.
[37] Lewis GDJO. Why mothers die: Confidential enquiries into maternal deaths in
the United Kingdom 1997–99. London: RCOG Press; 2001.
[38] Goyaux N, Leke R, Keita N, Thonneau P. Ectopic pregnancy in African
developing countries. Acta Obstet Gynecol Scand 2003;82:305–12.
[39] Brown S. Miscarriage and its associations. Semin Reprod Med
2008;26:391–400.
[40] Maconochie N, Doyle P, Prior S, Simmons R. Risk factors for first trimester
miscarriage–results from a UK-population-based case-control study. BJOG
2007;114:170–86.
[41] Olsen J, Skov T. Design options and methodological fallacies in the studies of
reproductive failures. Environ Health Perspect 1993;101(Suppl. 2):145–52.
[42] Tong S, Kaur A, Walker SP, Bryant V, Onwude JL, Permezel M. Miscarriage risk
for asymptomatic women after a normal first-trimester prenatal visit. Obstet
Gynecol 2008;111:710–4.
[43] Chrousos GP, Torpy DJ, Gold PW. Interactions between the hypothalamic-
pituitary-adrenal axis and the female reproductive system: clinical
implications. Ann Intern Med 1998;129:229–40.
[44] Paarlberg KM, Vingerhoets AJ, Passchier J, Dekker GA, Van Geijn HP.
Psychosocial factors and pregnancy outcome: a review with emphasis on
methodological issues. J Psychosom Res 1995;39:563–95.
[45] Sandman CA, Wadhwa PD, Chicz-DeMet A, Dunkel-Schetter C, Porto M.
Maternal stress, HPA activity, and fetal/infant outcome. Ann N Y Acad Sci
1997;814:266–75.
[46] Smith R, Cubis J, Brinsmead M, Lewin T, Singh B, Owens P, et al. Mood
changes, obstetric experience and alterations in plasma cortisol, beta-
endorphin and corticotrophin releasing hormone during pregnancy and the
puerperium. J Psychosom Res 1990;34:53–69.
[47] Wadhwa PD, Dunkel-Schetter C, Chicz-DeMet A, Porto M, Sandman CA.
Prenatal psychosocial factors and the neuroendocrine axis in human
pregnancy. Psychosom Med 1996;58:432–46.
[48] Gold KJ, Dalton VK, Schwenk TL, Hayward RA. What causes pregnancy loss?
Preexisting mental illness as an independent risk factor. Gen Hosp Psychiatry
2007;29:207–13.
[49] Aoki K, Kajiura S, Matsumoto Y, Ogasawara M, Okada S, Yagami Y, et al.
Preconceptional natural-killer-cell activity as a predictor of miscarriage.
Lancet 1995;345:1340–2.
[50] Hori S, Nakano Y, Furukawa TA, Ogasawara M, Katano K, Aoki K, et al.
Psychosocial factors regulating natural-killer cell activity in recurrent
spontaneous abortions. Am J Reprod Immunol 2000;44:299–302.
[51] Seng JS, Oakley DJ, Sampselle CM, Killion C, Graham-Bermann S, Liberzon I.
Posttraumatic stress disorder and pregnancy complications. Obstet Gynecol
2001;97:17–22.
[52] Coste J, Job-Spira N, Fernandez H. Risk factors for spontaneous abortion: a
case-control study in France. Hum Reprod 1991;6:1332–7.
[53] Neugebauer R, Kline J, Stein Z, Shrout P, Warburton D, Susser M. Association
of stressful life events with chromosomally normal spontaneous abortion.
Am J Epidemiol 1996;143:588–96.
[54] Sugiura-Ogasawara M, Furukawa TA, Nakano Y, Hori S, Aoki K, Kitamura T.
Depression as a potential causal factor in subsequent miscarriage in recurrent
spontaneous aborters. Hum Reprod 2002;17:2580–4.
[55] Peterson HB, Xia Z, Hughes JM, Wilcox LS, Tylor LR, Trussell J. The risk of
ectopic pregnancy after tubal sterilization. U.S. Collaborative Review of
Sterilization Working Group. N Engl J Med 1997;336:762–7.
[56] Backman T, Rauramo I, Huhtala S, Koskenvuo M. Pregnancy during the use of
levonorgestrel intrauterine system. Am J Obstet Gynecol 2004;190:50–4.
[57] Sivin I. Dose- and age-dependent ectopic pregnancy risks with intrauterine
contraception. Obstet Gynecol 1991;78:291–8.
[58] Yao M, Tulandi T. Current status of surgical and nonsurgical management of
ectopic pregnancy. Fertil Steril 1997;67:421–33.
6574 C.E. Rouse et al. / Vaccine 35 (2017) 6563–6574[59] DeCherney AH, Cholst I, Naftolin F. Structure and function of the fallopian
tubes following exposure to diethylstilbestrol (DES) during gestation. Fertil
Steril 1981;36:741–5.
[60] Hillis SD, Owens LM, Marchbanks PA, Amsterdam LF, Mac Kenzie WR.
Recurrent chlamydial infections increase the risks of hospitalization for
ectopic pregnancy and pelvic inflammatory disease. Am J Obstet Gynecol
1997;176:103–7.
[61] Marcus SF, Brinsden PR. Analysis of the incidence and risk factors associated
with ectopic pregnancy following in-vitro fertilization and embryo transfer.
Hum Reprod 1995;10:199–203.
[62] Strandell A, Thorburn J, Hamberger L. Risk factors for ectopic pregnancy in
assisted reproduction. Fertil Steril 1999;71:282–6.
[63] Clayton HB, Schieve LA, Peterson HB, Jamieson DJ, Reynolds MA, Wright VC.
Ectopic pregnancy risk with assisted reproductive technology procedures.
Obstet Gynecol 2006;107:595–604.
[64] World Health Organization. Vaccines against influenza WHO position paper.
Weekly Epidemiol Rec/Relevé épidémiologique Hebdomadaire
2012;87:461–76.
[65] World Health Organization Global Advisory Committee on Vaccine Safety.
Safety of immunization during pregnancy: a review of the evidence; 2014.
[66] National Center for Immunization and Respiratory Diseases. General
recommendations on immunization – recommendations of the Advisory
Committee on Immunization Practices (ACIP). MMWR Recomm Rep
2011;60:1–64.
[67] Fell DB, Platt RW, Lanes A, Wilson K, Kaufman JS, Basso O, et al. Fetal death
and preterm birth associated with maternal influenza vaccination:
systematic review. BJOG 2015;122:17–26.
[68] McMillan M, Porritt K, Kralik D, Costi L, Marshall H. Influenza vaccination
during pregnancy: a systematic review of fetal death, spontaneous abortion,
and congenital malformation safety outcomes. Vaccine 2015;33:2108–17.
[69] Bratton KN, Wardle MT, Orenstein WA, Omer SB. Maternal influenza
immunization and birth outcomes of stillbirth and spontaneous abortion: a
systematic review and meta-analysis. Clin Infect Dis 2015;60:e11–9.
[70] Naleway AL, Smith WJ, Mullooly JP. Delivering influenza vaccine to pregnant
women. Epidemiol Rev 2006;28:47–53.
[71] Shimabukuro T. End-of-season update: 2014–2015 influenza vaccine safety
monitoring; 2015.
[72] World Health Organization. Vaccines against tetanus WHO position paper.
Weekly Epidemiol Rec/Relevé épidémiologique Hebdomadaire
2006;81:197–208.
[73] World Health Organization. Pertussis vaccines: WHO position paper. Weekly
Epidemiol Rec/Relevé épidémiologique Hebdomadaire 2015;90:433–60.
[74] Shakib JH, Korgenski K, Sheng X, Varner MW, Pavia AT, Byington CL. Tetanus,
diphtheria, acellular pertussis vaccine during pregnancy: pregnancy and
infant health outcomes. J Pediatr 2013;163. 1422-6.e1-4.
[75] Moro PL, Cragan J, Tepper N, Zheteyeva Y, Museru O, Lewis P, et al. Enhanced
surveillance of tetanus toxoid, reduced diphtheria toxoid, and acellular
pertussis (Tdap) vaccines in pregnancy in the Vaccine Adverse Event
Reporting System (VAERS), 2011–2015. Vaccine 2016;34:2349–53.
[76] Garland SM, Ault KA, Gall SA, Paavonen J, Sings HL, Ciprero KL, et al.
Pregnancy and infant outcomes in the clinical trials of a human
papillomavirus type 6/11/16/18 vaccine: a combined analysis of five
randomized controlled trials. Obstet Gynecol 2009;114:1179–88.
[77] Angelo M-G, David M-P, Zima J, Baril L, Dubin G, Arellano F, et al. Pooled
analysis of large and long-term safety data from the human papillomavirus-
16/18-AS04-adjuvanted vaccine clinical trial programme.
Pharmacoepidemiol Drug Saf 2014;23:466–79.
[78] Goss MA, Lievano F, Buchanan KM, Seminack MM, Cunningham ML, Dana A.
Final report on exposure during pregnancy from a pregnancy registry for
quadrivalent human papillomavirus vaccine. Vaccine 2015;33:3422–8.
[79] Moro PL, Zheteyeva Y, Lewis P, Shi J, Yue X, Museru OI, et al. Safety of
quadrivalent human papillomavirus vaccine (Gardasil) in pregnancy: adverse
events among non-manufacturer reports in the Vaccine Adverse Event
Reporting System, 2006–2013. Vaccine 2015;33:519–22.
[80] Zheteyeva Y, Moro PL, Yue X, Broder K. Safety of meningococcal
polysaccharide-protein conjugate vaccine in pregnancy: a review of the
Vaccine Adverse Event Reporting System. Am J Obstet Gynecol 2013;208.
478.e1-6.[81] Meningitis Vaccine Project News Digest 42 (Q4); 2014.
[82] World Health Organization. Technical note: MenAfriVacTM vaccine
campaigns in the African meningitis belt Use of vaccine in pregnant and
lactating women; 2010.
[83] Wak G, Williams J, Oduro A, Maure C, Zuber PLF, Black S. The safety of PsA-TT
in pregnancy: an assessment performed within the Navrongo health and
demographic surveillance site in Ghana. Clin Infect Dis 2015;61(Suppl. 5):
S489–92.
[84] Sukumaran L, McNeil MM, Moro PL, Lewis PW, Winiecki SK, Shimabukuro TT.
Adverse events following measles, mumps, and rubella vaccine in adults
reported to the vaccine adverse event reporting system (VAERS), 2003–2013.
Clin Infect Dis 2015;60:e58–65.
[85] da Silva e Sá GR, Camacho LAB, Stavola MS, Lemos XR, Basílio de Oliveira CA,
Siqueira MM. Pregnancy outcomes following rubella vaccination: a
prospective study in the state of Rio de Janeiro, Brazil, 2001–2002. J Infect
Dis 2011;204(Suppl. 2):S722–8.
[86] Badilla X, Morice A, Avila-Aguero ML, Saenz E, Cerda I, Reef S, et al. Fetal risk
associated with rubella vaccination during pregnancy. Pediatr Infect Dis J
2007;26:830–5.
[87] Castillo-Solórzano C, Reef SE, Morice A, Vascones N, Chevez AE, Castalia-
Soares R, et al. Rubella vaccination of unknowingly pregnant women during
mass campaigns for rubella and congenital rubella syndrome elimination, the
Americas 2001–2008. J Infect Dis 2011;204(Suppl. 2):S713–7.
[88] Wilson E, Goss MA, Marin M, Shields KE, Seward JF, Rasmussen SA, et al.
Varicella vaccine exposure during pregnancy: data from 10 Years of the
pregnancy registry. J Infect Dis 2008;197(Suppl. 2):S178–84.
[89] Ornoy A, Arnon J, Feingold M, Ben Ishai P. Spontaneous abortions following
oral poliovirus vaccination in first trimester. Lancet 1990;335:800.
[90] Kohl KS, Gidudu J, Bonhoeffer J, Braun MM, Buettcher M, Chen RT, et al. The
development of standardized case definitions and guidelines for adverse
events following immunization. Vaccine 2007;25:5671–4.
[91] Quinn JA, Munoz FM, Gonik B, Frau L, Cutland C, Mallett-Moore T, et al.
Preterm birth: case definition & guidelines for data collection, analysis, and
presentation of immunisation safety data. Vaccine 2016;34:6047–56.
[92] Kowaleski J. State definitions and reporting requirements for live births, fetal
deaths, and induced terminations of pregnancy (1997 revision). Hyattsville,
Maryland: National Center for Health Statistics; 1997.
[93] World Health Organization. Neonatal and perinatal mortality: country,
regional and global estimates. Geneva, Switzerland; 2006.
[94] Guideline on the Exposure to Medicinal Products during Pregnancy: Need for
Post-authorization Data. European Medicines Agency (Committee for
Medicinal Products for Human Use); 2005.
[95] Royal College of Obstetricians & Gynaecoloists. Registration of stillbirths and
certification for pregnancy loss before 24 weeks of gestation (Good Practice
No. 4); 2005.
[96] Committee on Practice Bulletins—Gynecology. The American College of
Obstetricians and Gynecologists Practice Bulletin no. 150. Early pregnancy
loss. Obstet Gynecol 2015;125:1258–67.
[97] ICH Harmonised Tripartite Guidelines: Guidelines for Clinical Safety
assessment (E2a-e). International conference on harmonisation of technical
requirements for registration of pharmaceuticals for human use (ICH); 2004.
[98] Council for International Organizations of Medical Sciences. CIOMS form I; n.
d. <http://www.cioms.ch/index.php/cioms-form-i> (accessed June 23, 2016).
[99] Moher D, Schulz KF, Altman D. CONSORT Group (Consolidated Standards of
Reporting Trials). The CONSORT statement: revised recommendations for
improving the quality of reports of parallel-group randomized trials. JAMA
2001;285:1987–91.
[100] Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the
quality of reports of meta-analyses of randomised controlled trials: the
QUOROM statement. Quality of Reporting of Meta-analyses. Lancet
1999;354:1896–900.
[101] Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-
analysis of observational studies in epidemiology: a proposal for reporting.
Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.
JAMA 2000;283:2008–12.
